WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the preliminary list of presenting companies for the 16th Annual BIO CEO & Investor Conference to be held February 10-11, 2014 in New York City. Presenting companies are hand-selected for the event, and consist of a selection of mid- to large-cap established public as well as late-stage private companies from around the globe. These companies typically have a clinical stage program centered around therapeutics, molecular diagnostics or a platform technology, as well as an upcoming clinical, regulatory or corporate catalyst.
“2013 has been a banner year for the biotech sector. We have seen more than 40 biotech IPOs this year alone, 15 of which will be represented through company presentations,” said BIO president & CEO Jim Greenwood. “The BIO CEO and Investor Conference will allow investors and companies alike to engage amongst their peers and discover how best to take advantage of the current market opportunities for the year ahead.”
The following companies are slated to present at this year’s conference:
Public Companies:
- ACADIA Pharmaceuticals
- AcelRx Pharmaceuticals
- Advanced Cell Technology
- Advaxis
- Agenus
- Alcobra Ltd.
- Alexion Pharmaceuticals
- Alkermes plc
- Allergan
- Alnylam Pharmaceuticals
- Amarantus Bioscience
- Anavex Life Sciences Corp.
- Anthera Pharmaceuticals
- AntriaBio
- Apricus Biosciences
- Aradigm Corp.
- Arena Pharmaceuticals
- Athersys
- Auxilium Pharmaceuticals
- Avita Medical
- Bavarian Nordic A/S
- BIND Therapeutics*
- Biodel
- BioLineRx
- Biotie Therapies
- Catalyst Pharmaceutical Partners
- CEL-SCI Corporation
- Cempra
- Chimerix*
- Cleveland BioLabs
- Codexis
- Columbia Laboratories
- Conatus Pharmaceuticals*
- Cyclacel Pharmaceuticals
- CytoDyn
- Cytokinetics
- CytRx Corporation
- DARA BioSciences
- DURECT Corporation
- Epizyme*
- Exelixis
- FivePrime Therapeutics*
- Galectin Therapeutic
- Galena Biopharma
- GENFIT
- GenSpera
- GTx
- Heat Biologics*
- Horizon Pharma
- Idera Pharmaceuticals
- Ignyta
- ImmunoCellular Therapeutics
- Immunovaccine
- Innovus Pharmaceuticals
- Inovio Pharmaceuticals
- Intra-Cellular Therapies
- Intrexon Corporation*
- KaloBios Pharmaceuticals*
- Keryx Biopharmaceuticals
- La Jolla Pharmaceutical Company
- Lexicon Pharmaceuticals
- Lpath
- Mast Therapeutics
- Medigene AG
- Merck Serono
- Mesoblast
- Navidea Biopharmaceuticals
- NeoStem
- Neuralstem
- Newron Pharmaceuticals S.p.A.
- Northwest Biotherapeutics
- NovaBay Pharmaceuticals
- Novelos Therapeutics
- OHR Pharmaceutical
- OncoMed Pharmaceuticals*
- Onconova Therapeutics*
- OncoSec Medical
- Opexa Therapeutics
- Ophthotech*
- Oragenics
- Orexigen Therapeutics
- OvaScience
- OXiGENE
- PDL BioPharma
- Prima BioMed
- Prometic LifeSciences
- Prosensa
- pSiVida
- Regado Biosciences*
- Relypsa*
- ReNeuron Group plc
- Repros Therapeutics
- Resverlogix
- Rexahn Pharmaeuticals
- Rigel Pharmaceuticals
- RXi Pharmaceuticals
- Sanofi
- SciClone Pharmaceuticals
- Selvita S.A.
- SIGA Technologies
- Soligenix
- Sorrento Therapeutics
- Stallergenes
- Stem Cell Therapeutics
- StemCells Inc.
- Stemline Therapeutics*
- Swedish Orphan Biovitrum AB
- SYGNIS AG
- Synergy Pharmaceuticals
- Synthetic Biologics
- Targacept
- Tekmira Pharmaceuticals Corporation
- Tetraphase Pharmaceuticals*
- TG Therapeutics
- The Medicines Company
- TiGenix N.V.
- Tonix Pharmaceuticals
- Transition Therapeutics
- TrovaGene
- Verastem
- ZIOPHARM Oncology
Private Companies:
- Aduro Biotech
- ALS Therapy Development Institute
- Cerecor
- CymaBay
- Kadmon Corporation
- KineMed
- MaxCyte
- Melinta Therapeutics
- Mirna Therapeutics
- Pieris AG
- Polynoma
- Proteon Therapeutics
- Q Therapeutics
- Sutro Biopharma
- Symphogen
- Trevena
- TxCell SA
- XDx
*indicates 2013 IPO
Check back often as new presenters are continuously being added. Companies interested in presenting their story can submit an application here.
In addition to Company Presentations, the conference will host Fireside Chats, Therapeutic Workshops, Business Roundtables and the opportunity to arrange meetings between investors, companies and industry executives via BIO’s One-on-One Partnering™ System.
Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration. Equity research analysts from investment banking institutions also qualify as investors. Media registration also is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks Leerink Swann and ROTH Capital Partners, LLC.
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
Upcoming BIO Events
BIO
CEO & Investor Conference
February 10–11, 2014
New
York, NY
BIO
Asia International Conference
April 8-9, 2014
Tokyo, Japan
World
Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia,
PA
BIO
International Convention
June 23-26, 2014
San Diego, CA
Livestock
Biotech Summit
September 16-18, 2014
Sioux Falls, SD
